'No convincing alternative' to aspirin for secondary cardiovascular prevention, meta-analysis suggests

In a meta-analysis of randomised trials, patients who received a P2Y12 inhibitor for secondary prevention of cardiovascular events had a borderline reduction in the risk of myocardial infarction compared with those who received aspirin.

by Chloe Harman
P2Y12 inhibitors provide more profound platelet inhibition than aspirin but appear to offer similar clinical benefits in secondary cardiovascular prevention. | GETTY IMAGES
P2Y12 inhibitors provide more profound platelet inhibition than aspirin but appear to offer similar clinical benefits in secondary cardiovascular prevention. | GETTY IMAGES

Sign in to continue

Sign In

Trouble signing in?

Reset password: Click here

Need help? Email us

Register

FREE

  • Limited free articles a month 
  • Free email bulletins

Register Now

Subscribe now

Benefits include:

  • Full site access
  • Subscriber exclusive content
  • Exclusive bulletins

Choose a package